Genesis Therapeutics
Unlock tough protein targets with Genesis Therapeutics’ GEMS and Pearl molecular AI.
About
Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines.
Details
Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines. The company has secured over $256M in funding from top investors including a16z, Fidelity, BlackRock, and NVIDIA, and established major collaborations with Gilead and Incyte (including a $120M upfront expansion).
Key Features
- Advanced molecular AI platform integrating deep learning and physics-based ML
- Proprietary GEMS platform for AI-driven molecular design
- Pearl foundation model for protein–ligand structure prediction
- Reported performance exceeding AlphaFold 3 on key protein–ligand benchmarks
- Focus on unlocking tough, chemically complex protein targets
- Industry-leading speed with high potency and selectivity in discovery workflows
- Scalable small-molecule discovery across large chemical spaces
- Active internal pipeline across multiple therapeutic areas (e.g., immunology, inflammation)
- Dedicated AI research advancing state-of-the-art molecular modeling
- Drug pipeline development enabled by AI-guided design and triage
Use Cases
- Medicinal chemists: Rapidly optimize potency and selectivity using AI-guided design and structure–activity insights from GEMS.
- Computational biologists: Predict protein–ligand structures at scale with Pearl to prioritize designs and de-risk experiments.
- Drug discovery teams: Unlock hard protein targets previously considered intractable to expand the addressable target space.
- Pharma R&D leaders: Accelerate hit finding and lead optimization to compress cycle times and improve portfolio velocity.
- Biotech startups: Leverage platform expertise via partnerships to build high-quality pipelines with fewer resources.
- Structural biologists: Generate high-confidence binding poses to inform assay design and crystallography or cryo-EM efforts.
- Project managers: Triage large design spaces efficiently, focusing wet-lab effort on the most promising candidates.
- BD and alliance teams: Structure AI-driven collaborations (e.g., with Incyte) to pursue new small-molecule programs jointly.
- Therapeutic area leads: Apply molecular AI to immunology and inflammation targets to advance differentiated candidates.
- Investors and advisors: Evaluate platform differentiation, benchmark leadership, and pipeline scalability in molecular AI.
Pros & Cons
Pros
- State-of-the-art protein-ligand structure prediction, reportedly outperforming AlphaFold 3
- Proprietary GEMS platform integrates deep learning and physics for efficient molecular design
- Strong partnerships with major pharma (Gilead, Incyte) with significant upfront payments ($65M+ across deals)
- Well-funded with over $256M in total funding from top investors (a16z, Fidelity, BlackRock, NVIDIA)
- Iterative learning loop: each design cycle generates new data to continuously improve AI models
- Focus on difficult, chemically complex targets that are intractable to traditional approaches
Cons
- Pricing not publicly disclosed; requires contacting sales (pricing model: contact)
- Internal pipeline details are limited; most progress is demonstrated through partnerships
- Platform complexity may require significant expertise in both AI and drug discovery to adopt
- Relies on proprietary datasets and models, which may limit external validation and reproducibility
Frequently Asked Questions
What is Genesis Therapeutics' main focus?
Genesis develops industry-leading molecular AI to unlock tough protein targets and invent small-molecule medicines with unprecedented potency and selectivity.
What is the GEMS platform?
GEMS is Genesis’ proprietary AI platform that synthesizes AI and physics research to find drug candidates against difficult targets with industry-leading speed, potency, and selectivity.
What is Pearl?
Pearl is Genesis’ proprietary foundation model for protein–ligand structure prediction, reported to outperform frontier models like AlphaFold 3 on key benchmarks.
When was Genesis founded, and what is its funding history?
Founded in 2019, Genesis raised a $4.1M seed (a16z), a $52M Series A (2020, Rock Springs Capital), and a $200M oversubscribed Series B (2023, co-led by a16z with investors including Fidelity, BlackRock, and NVIDIA).
Who leads Genesis Therapeutics?
CEO and co-founder Evan Feinberg, Ph.D.; COO Will McCarthy; and CSO Shifeng Pan, Ph.D., a veteran drug developer with FDA-approved programs.
What does Genesis’ pipeline involve?
AI-enabled small-molecule drug candidates with high potency and selectivity for chemically complex targets, spanning multiple therapeutic areas such as immunology and inflammation.
What recent collaborations has Genesis announced?
Genesis announced a strategic AI-focused research collaboration with Incyte to leverage GEMS for discovering breakthrough small-molecule therapeutics.
Where is Genesis headquartered?
Genesis is headquartered in San Diego, where its team of chemists and biologists deploys GEMS to progress the internal pipeline.
How does GEMS combine AI and physics-based machine learning?
GEMS integrates deep learning with physics-informed models to predict protein–ligand interactions and guide design toward potent, selective small molecules.
Which therapeutic areas does Genesis target?
Genesis applies its platform across multiple disease areas, including immunology and inflammation, while pursuing additional areas with high unmet need.